CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Apollon Formularies PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Apollon Formularies PLC
Suite 3b, 38 Jermyn Street
Phone: +44 2074400640p:+44 2074400640 LONDON, SW1Y 6DN  United Kingdom Ticker: APOLAPOL
Business Summary
Apollon Formularies plc is a United Kingdom-based medical cannabis pharmaceutical company. The Company is engaged in specializing in research and treatment of patients with cancer and chronic pain. The Company has hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products. Its products with trademarks include APOLLON-Full Extract Cannabis Oil (FECO) Vape, APOLLON FECO Oral Tincture-30ml Bottle, and APOLLON FECO Prescribed Capsules. It also includes Apollon NAUSEA Apollon PAIN, Apollon SLEEP, Apollon ANTI-INFLAMMATORY, Apollon SEIZURES, Apollon APPETITE, and Apollon CANCER. It offers services, including cultivation, processing and extraction, international cancer institute, retail product sales, Apollon Negril facility, research and development, and bespoke treatments and products. The Company’s wholly owned subsidiary is Apollon Formularies Ltd.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2021Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board David A.Lenigas 61 6/30/2016 4/24/2013
Chief Operating Officer SteneJacobs
Non-Executive Director Hamish H.Harris 51 6/30/2016 10/24/2012
Non-Executive Director Donald I.Strang 4/28/2016 10/24/2012

Business Names
Business Name
3DD
3DR
AFRI
APOL

General Information
Number of Employees: 18 (As of 6/30/2011)
Outstanding Shares: 771,191,266 (As of 6/30/2023)
Stock Exchange: AQS
Fax Number: +44 2074400641


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024